ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,047 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 176-200 of 1,000 matching filings.

Per page
25
Current page
8
6-K File 001-11960

DIRECTOR DECLARATION

Filing date
21 May 2025
Reporting date
21 May 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ACQUISITION OF ESOBIOTEC COMPLETED

Filing date
20 May 2025
Reporting date
20 May 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER

Filing date
09 May 2025
Reporting date
09 May 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER

Filing date
07 May 2025
Reporting date
07 May 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL

Filing date
06 May 2025
Reporting date
06 May 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS

Filing date
02 May 2025
Reporting date
02 May 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
01 May 2025
Reporting date
01 May 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 May 2025
Reporting date
01 May 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL

Filing date
29 Apr 2025
Reporting date
29 Apr 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON CAPITELLO-280 PHASE III TRIAL

Filing date
29 Apr 2025
Reporting date
29 Apr 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

1ST QUARTER RESULTS

Filing date
29 Apr 2025
Reporting date
29 Apr 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A File 005-55247

SCHEDULE 13G/A filing

Filing date
23 Apr 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC

Filing date
22 Apr 2025
Reporting date
22 Apr 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

RESULT OF AGM

Filing date
11 Apr 2025
Reporting date
11 Apr 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
10 Apr 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN EU FOR AEGEAN

Filing date
04 Apr 2025
Reporting date
04 Apr 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER

Filing date
04 Apr 2025
Reporting date
04 Apr 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Apr 2025
Reporting date
01 Apr 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL

Filing date
31 Mar 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN THE US FOR BLADDER CANCER

Filing date
31 Mar 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING

Filing date
21 Mar 2025
Reporting date
21 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT

Filing date
17 Mar 2025
Reporting date
17 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC

Filing date
17 Mar 2025
Reporting date
17 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA TO ACQUIRE ESOBIOTEC

Filing date
17 Mar 2025
Reporting date
17 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

HOLDING(S) IN COMPANY

Filing date
12 Mar 2025
Reporting date
12 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .